NURS 6521: Advanced Pharmacology
Midterm Examination | 2025/2026
100 Multiple-Choice Questions with Correct Answers and Rationales
Walden University | MSN/DNP Curriculum
Assessment: Weeks 1–6 Learning Resources | Time Limit: 2 Hours
Format: Multiple-Choice | Weight: 100 Points (25% of Course Grade)
1
,Section 1: Pharmacokinetics & Pharmacodynamics Principles
Q1. A graduate nursing student is reviewing the pharmacokinetic profile of a newly prescribed medication. The
student correctly identifies that which of the following processes describes the movement of a drug from its site
of administration into the bloodstream?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Correct Answer: B. Absorption
Rationale: Absorption is the process by which a drug moves from its site of administration into the systemic circulation.
This process is influenced by the route of administration, drug solubility, surface area, and first-pass metabolism.
Distribution (A) refers to the movement of a drug from the bloodstream to tissues and organs. Metabolism (C) is the
biotransformation of drugs, primarily by the liver via cytochrome P450 enzymes. Excretion (D) is the elimination of drugs
from the body, primarily through the kidneys (urine) or liver (bile). Understanding ADME principles is foundational for
advanced practice nurses in optimizing drug therapy.
Q2. A patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass metabolism. The
advanced practice nurse anticipates which of the following effects?
A. Decreased bioavailability of the drug
B. Increased bioavailability of the drug
C. No change in drug effect
D. Accelerated renal excretion
Correct Answer: B. Increased bioavailability of the drug
Rationale: First-pass metabolism occurs when a drug is absorbed from the GI tract and passes through the liver before
entering systemic circulation. In liver cirrhosis, hepatic blood flow and metabolic capacity are reduced, meaning more of
the drug reaches systemic circulation unchanged, resulting in increased bioavailability. This increases the risk of drug
toxicity. Option A is incorrect because decreased hepatic function leads to increased, not decreased, bioavailability. Option
C is incorrect because liver disease significantly alters drug metabolism. Option D describes an unrelated process. APRNs
must reduce dosages of drugs with high first-pass metabolism in patients with hepatic impairment.
Q3. A drug has a half-life of 6 hours. Approximately how long will it take for the drug to reach steady-state
concentration with repeated dosing?
A. 6 hours
B. 12 hours
C. 24 hours
D. 30 hours
Correct Answer: D. 30 hours
Rationale: Steady state is achieved in approximately 4 to 5 half-lives. For a drug with a 6-hour half-life: 4 half-lives = 24
hours, 5 half-lives = 30 hours. At steady state, the rate of drug administration equals the rate of elimination. A loading dose
may be used to achieve therapeutic levels more rapidly. Options A and B represent only 1 and 2 half-lives respectively,
which are insufficient. Option C represents approximately 4 half-lives, which achieves about 94% of steady state, but 5 half-
2
,lives (30 hours) is the accepted standard for full steady-state approximation. This principle is critical for APRNs when
titrating medications such as anticonvulsants, antiarrhythmics, and anticoagulants.
Q4. The nurse is administering a highly protein-bound drug (98% bound) to a patient who is also taking another
highly protein-bound drug. The nurse understands that this interaction may result in which of the following?
A. Decreased therapeutic effect of both drugs
B. Increased free (active) drug concentration leading to toxicity
C. Accelerated metabolism of both drugs
D. Enhanced renal excretion of both drugs
Correct Answer: B. Increased free (active) drug concentration leading to toxicity
Rationale: When two highly protein-bound drugs are administered concurrently, they compete for binding sites on plasma
proteins (primarily albumin). Displacement of one drug from protein-binding sites increases the free (unbound),
pharmacologically active fraction of the displaced drug, potentially leading to toxicity. Only the unbound fraction can cross
cell membranes and exert therapeutic or toxic effects. Option A describes decreased effect, which would occur with reduced
free drug, not increased. Options C and D are unrelated to protein binding displacement. Examples of highly protein-bound
drugs include warfarin, phenytoin, and valproic acid, making monitoring essential when co-administered.
Q5. A patient is prescribed a drug with a narrow therapeutic index. Which of the following nursing interventions
is most critical?
A. Administer the drug with food to enhance absorption
B. Monitor serum drug levels regularly
C. Encourage the patient to take the drug PRN
D. Administer the drug every other day
Correct Answer: B. Monitor serum drug levels regularly
Rationale: A drug with a narrow therapeutic index has a small margin between the effective dose and the toxic dose.
Regular serum drug level monitoring is essential to ensure therapeutic efficacy while avoiding toxicity. Classic examples
include digoxin, phenytoin, lithium, theophylline, and warfarin. Option A is not specifically related to therapeutic index
management. Option C is incorrect because narrow therapeutic index drugs require consistent dosing schedules, not PRN
administration. Option D is incorrect because dosing intervals are determined by pharmacokinetics, not arbitrary
scheduling. Therapeutic drug monitoring (TDM) is a core competency for APRNs managing these medications.
Q6. The advanced practice nurse is explaining the mechanism of a competitive antagonist to a nursing student.
Which of the following best describes a competitive antagonist?
A. Binds irreversibly to the receptor, permanently inactivating it
B. Binds to the receptor and produces the opposite effect of the agonist
C. Competes with the agonist for the same receptor site and can be overcome by increasing agonist concentration
D. Acts at a different site on the receptor to reduce the maximum response of the agonist
Correct Answer: C. Competes with the agonist for the same receptor site and can be overcome by increasing
agonist concentration
Rationale: A competitive antagonist binds to the same receptor site as the agonist but does not activate it. The antagonism
is surmountable, meaning increasing the agonist concentration can overcome the blockade. Examples include naloxone
(opioid antagonist) and propranolol (beta-blocker). Option A describes an irreversible (noncompetitive) antagonist. Option
3
, B describes an inverse agonist, which produces effects opposite to the agonist at the same receptor. Option D describes a
noncompetitive antagonist that binds to an allosteric site and reduces the maximum agonist response regardless of agonist
concentration. Understanding receptor pharmacology is essential for predicting drug interactions and therapeutic
outcomes.
Q7. A 70-year-old patient with chronic kidney disease (GFR 25 mL/min) is prescribed a renally eliminated drug.
The APRN should anticipate which pharmacokinetic change?
A. Increased rate of hepatic metabolism
B. Decreased drug half-life requiring more frequent dosing
C. Prolonged drug half-life requiring dosage reduction
D. Increased protein binding of the drug
Correct Answer: C. Prolonged drug half-life requiring dosage reduction
Rationale: In chronic kidney disease with reduced GFR, the renal clearance of drugs eliminated primarily by the kidneys is
decreased. This leads to drug accumulation, prolonged half-life, and increased risk of toxicity. The APRN must reduce the
dose or extend the dosing interval. Option A is incorrect because renal impairment does not directly affect hepatic
metabolism. Option B is incorrect because decreased clearance leads to increased half-life, requiring less frequent dosing.
Option D is incorrect because CKD often leads to decreased protein binding due to uremic toxins displacing drugs from
albumin. Many medications, including gabapentin, lithium, and certain antibiotics, require renal dose adjustments
documented in prescribing references.
Q8. A drug that is a CYP3A4 inhibitor is prescribed to a patient who is also taking a CYP3A4 substrate. The
nurse anticipates which effect?
A. Decreased plasma concentration of the substrate drug
B. Increased plasma concentration of the substrate drug with risk of toxicity
C. No clinically significant interaction
D. Accelerated elimination of the substrate drug
Correct Answer: B. Increased plasma concentration of the substrate drug with risk of toxicity
Rationale: CYP3A4 is the most abundant cytochrome P450 enzyme and metabolizes approximately 50% of all medications.
A CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin, grapefruit juice, ritonavir) blocks the metabolism of CYP3A4
substrate drugs (e.g., simvastatin, amlodipine, midazolam), leading to increased plasma concentrations and potential
toxicity. Option A describes the effect of a CYP inducer, not inhibitor. Option C is incorrect because CYP3A4 interactions
are clinically significant. Option D describes induction, not inhibition. APRNs must review all medications for CYP-
mediated interactions before prescribing.
Q9. The term 'bioavailability' is best defined as which of the following?
A. The rate at which a drug is metabolized by the liver
B. The fraction of the administered drug that reaches systemic circulation unchanged
C. The volume of distribution of a drug in the body
D. The minimum effective concentration of a drug
Correct Answer: B. The fraction of the administered drug that reaches systemic circulation unchanged
Rationale: Bioavailability (F) is the fraction or percentage of an administered drug that reaches the systemic circulation in
an active, unchanged form. Intravenous drugs have 100% bioavailability (F = 1.0), while oral drugs typically have lower
4
Midterm Examination | 2025/2026
100 Multiple-Choice Questions with Correct Answers and Rationales
Walden University | MSN/DNP Curriculum
Assessment: Weeks 1–6 Learning Resources | Time Limit: 2 Hours
Format: Multiple-Choice | Weight: 100 Points (25% of Course Grade)
1
,Section 1: Pharmacokinetics & Pharmacodynamics Principles
Q1. A graduate nursing student is reviewing the pharmacokinetic profile of a newly prescribed medication. The
student correctly identifies that which of the following processes describes the movement of a drug from its site
of administration into the bloodstream?
A. Distribution
B. Absorption
C. Metabolism
D. Excretion
Correct Answer: B. Absorption
Rationale: Absorption is the process by which a drug moves from its site of administration into the systemic circulation.
This process is influenced by the route of administration, drug solubility, surface area, and first-pass metabolism.
Distribution (A) refers to the movement of a drug from the bloodstream to tissues and organs. Metabolism (C) is the
biotransformation of drugs, primarily by the liver via cytochrome P450 enzymes. Excretion (D) is the elimination of drugs
from the body, primarily through the kidneys (urine) or liver (bile). Understanding ADME principles is foundational for
advanced practice nurses in optimizing drug therapy.
Q2. A patient with liver cirrhosis is prescribed a medication that undergoes extensive first-pass metabolism. The
advanced practice nurse anticipates which of the following effects?
A. Decreased bioavailability of the drug
B. Increased bioavailability of the drug
C. No change in drug effect
D. Accelerated renal excretion
Correct Answer: B. Increased bioavailability of the drug
Rationale: First-pass metabolism occurs when a drug is absorbed from the GI tract and passes through the liver before
entering systemic circulation. In liver cirrhosis, hepatic blood flow and metabolic capacity are reduced, meaning more of
the drug reaches systemic circulation unchanged, resulting in increased bioavailability. This increases the risk of drug
toxicity. Option A is incorrect because decreased hepatic function leads to increased, not decreased, bioavailability. Option
C is incorrect because liver disease significantly alters drug metabolism. Option D describes an unrelated process. APRNs
must reduce dosages of drugs with high first-pass metabolism in patients with hepatic impairment.
Q3. A drug has a half-life of 6 hours. Approximately how long will it take for the drug to reach steady-state
concentration with repeated dosing?
A. 6 hours
B. 12 hours
C. 24 hours
D. 30 hours
Correct Answer: D. 30 hours
Rationale: Steady state is achieved in approximately 4 to 5 half-lives. For a drug with a 6-hour half-life: 4 half-lives = 24
hours, 5 half-lives = 30 hours. At steady state, the rate of drug administration equals the rate of elimination. A loading dose
may be used to achieve therapeutic levels more rapidly. Options A and B represent only 1 and 2 half-lives respectively,
which are insufficient. Option C represents approximately 4 half-lives, which achieves about 94% of steady state, but 5 half-
2
,lives (30 hours) is the accepted standard for full steady-state approximation. This principle is critical for APRNs when
titrating medications such as anticonvulsants, antiarrhythmics, and anticoagulants.
Q4. The nurse is administering a highly protein-bound drug (98% bound) to a patient who is also taking another
highly protein-bound drug. The nurse understands that this interaction may result in which of the following?
A. Decreased therapeutic effect of both drugs
B. Increased free (active) drug concentration leading to toxicity
C. Accelerated metabolism of both drugs
D. Enhanced renal excretion of both drugs
Correct Answer: B. Increased free (active) drug concentration leading to toxicity
Rationale: When two highly protein-bound drugs are administered concurrently, they compete for binding sites on plasma
proteins (primarily albumin). Displacement of one drug from protein-binding sites increases the free (unbound),
pharmacologically active fraction of the displaced drug, potentially leading to toxicity. Only the unbound fraction can cross
cell membranes and exert therapeutic or toxic effects. Option A describes decreased effect, which would occur with reduced
free drug, not increased. Options C and D are unrelated to protein binding displacement. Examples of highly protein-bound
drugs include warfarin, phenytoin, and valproic acid, making monitoring essential when co-administered.
Q5. A patient is prescribed a drug with a narrow therapeutic index. Which of the following nursing interventions
is most critical?
A. Administer the drug with food to enhance absorption
B. Monitor serum drug levels regularly
C. Encourage the patient to take the drug PRN
D. Administer the drug every other day
Correct Answer: B. Monitor serum drug levels regularly
Rationale: A drug with a narrow therapeutic index has a small margin between the effective dose and the toxic dose.
Regular serum drug level monitoring is essential to ensure therapeutic efficacy while avoiding toxicity. Classic examples
include digoxin, phenytoin, lithium, theophylline, and warfarin. Option A is not specifically related to therapeutic index
management. Option C is incorrect because narrow therapeutic index drugs require consistent dosing schedules, not PRN
administration. Option D is incorrect because dosing intervals are determined by pharmacokinetics, not arbitrary
scheduling. Therapeutic drug monitoring (TDM) is a core competency for APRNs managing these medications.
Q6. The advanced practice nurse is explaining the mechanism of a competitive antagonist to a nursing student.
Which of the following best describes a competitive antagonist?
A. Binds irreversibly to the receptor, permanently inactivating it
B. Binds to the receptor and produces the opposite effect of the agonist
C. Competes with the agonist for the same receptor site and can be overcome by increasing agonist concentration
D. Acts at a different site on the receptor to reduce the maximum response of the agonist
Correct Answer: C. Competes with the agonist for the same receptor site and can be overcome by increasing
agonist concentration
Rationale: A competitive antagonist binds to the same receptor site as the agonist but does not activate it. The antagonism
is surmountable, meaning increasing the agonist concentration can overcome the blockade. Examples include naloxone
(opioid antagonist) and propranolol (beta-blocker). Option A describes an irreversible (noncompetitive) antagonist. Option
3
, B describes an inverse agonist, which produces effects opposite to the agonist at the same receptor. Option D describes a
noncompetitive antagonist that binds to an allosteric site and reduces the maximum agonist response regardless of agonist
concentration. Understanding receptor pharmacology is essential for predicting drug interactions and therapeutic
outcomes.
Q7. A 70-year-old patient with chronic kidney disease (GFR 25 mL/min) is prescribed a renally eliminated drug.
The APRN should anticipate which pharmacokinetic change?
A. Increased rate of hepatic metabolism
B. Decreased drug half-life requiring more frequent dosing
C. Prolonged drug half-life requiring dosage reduction
D. Increased protein binding of the drug
Correct Answer: C. Prolonged drug half-life requiring dosage reduction
Rationale: In chronic kidney disease with reduced GFR, the renal clearance of drugs eliminated primarily by the kidneys is
decreased. This leads to drug accumulation, prolonged half-life, and increased risk of toxicity. The APRN must reduce the
dose or extend the dosing interval. Option A is incorrect because renal impairment does not directly affect hepatic
metabolism. Option B is incorrect because decreased clearance leads to increased half-life, requiring less frequent dosing.
Option D is incorrect because CKD often leads to decreased protein binding due to uremic toxins displacing drugs from
albumin. Many medications, including gabapentin, lithium, and certain antibiotics, require renal dose adjustments
documented in prescribing references.
Q8. A drug that is a CYP3A4 inhibitor is prescribed to a patient who is also taking a CYP3A4 substrate. The
nurse anticipates which effect?
A. Decreased plasma concentration of the substrate drug
B. Increased plasma concentration of the substrate drug with risk of toxicity
C. No clinically significant interaction
D. Accelerated elimination of the substrate drug
Correct Answer: B. Increased plasma concentration of the substrate drug with risk of toxicity
Rationale: CYP3A4 is the most abundant cytochrome P450 enzyme and metabolizes approximately 50% of all medications.
A CYP3A4 inhibitor (e.g., ketoconazole, clarithromycin, grapefruit juice, ritonavir) blocks the metabolism of CYP3A4
substrate drugs (e.g., simvastatin, amlodipine, midazolam), leading to increased plasma concentrations and potential
toxicity. Option A describes the effect of a CYP inducer, not inhibitor. Option C is incorrect because CYP3A4 interactions
are clinically significant. Option D describes induction, not inhibition. APRNs must review all medications for CYP-
mediated interactions before prescribing.
Q9. The term 'bioavailability' is best defined as which of the following?
A. The rate at which a drug is metabolized by the liver
B. The fraction of the administered drug that reaches systemic circulation unchanged
C. The volume of distribution of a drug in the body
D. The minimum effective concentration of a drug
Correct Answer: B. The fraction of the administered drug that reaches systemic circulation unchanged
Rationale: Bioavailability (F) is the fraction or percentage of an administered drug that reaches the systemic circulation in
an active, unchanged form. Intravenous drugs have 100% bioavailability (F = 1.0), while oral drugs typically have lower
4
